.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,011,848

« Back to Dashboard

Summary for Patent: 7,011,848

Title:Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor
Abstract:An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day "nocturnally," that is in the evening or at night.
Inventor(s): Bova; David J. (Hollywood, FL)
Assignee: KOS Pharmaceuticals, Inc. (Miami, FL)
Application Number:09/470,603
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Formulation;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 4th percentile
Forward Citations: 0th percentile
Patent PDF download available with subscription

No matches for this query

International Patent Family for Patent: 7,011,848

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2574987<disabled in preview>
Canada2283322<disabled in preview>
Canada2283159<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc